## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-21 (cancelled)

Claim 22 (currently amended): A ~~composition~~ conjugate for inducing specific B cell anergy to a T cell dependent immunogen implicated in an antibody-mediated pathology in an individual suffering from the pathology ~~comprising a plurality of a conjugate~~, wherein said conjugate is formable by the conjugation of:

(a) at least two analog molecules of the immunogen, wherein (1) said analog molecules bind specifically to surface antibody on B cells to which the T cell-dependent immunogen binds specifically, ~~and wherein~~ (2) the analog molecules lack T cell epitopes, and (3) the analog molecules are selected from the group consisting of carbohydrates, lipids, lipopolysaccharides, polypeptides, peptides, proteins, glycoproteins, and lipoproteins; and

(b) a chemically defined valency platform molecule, ~~wherein:~~ wherein (1) the chemically defined valency platform molecule comprises branching groups[[;]] (2) the valency of the platform molecule is provided by attachment sites located at termini of the valency platform molecule; and (3) the valency platform molecule is chemically defined in that the number of branching groups pre-determines the number of attachment sites.

~~the valency platform molecule contains a specific number of attachment sites whereby the valency of said platform molecule is defined;~~

~~wherein the molecular weight of the valency platform molecules is substantially homogeneous; and~~

~~the valency platform molecule has attachment sites at the same location~~.

Claim 23 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the branching groups are derived from a functional group selected from the group consisting of a diamino acid, a triamine, and an amino diacid.

Claim 24 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the analog molecules are the same.

Claim 25 (currently amended): The ~~composition~~ conjugate of claim 22, wherein said conjugate comprises four analog molecules.

Clam 26 (cancelled)

Claim 27 (cancelled)

Clam 28 (withdrawn-currently amended): The ~~composition~~ conjugate of claim 22, wherein the analog molecules are proteins ~~molecule is a protein~~.

Clam 29 (currently amended): ~~The composition~~ A pharmaceutically acceptable composition comprising the conjugate of claim 22, and ~~comprising~~ a pharmaceutically acceptable carrier.

Claim 30 (previously presented): The composition of claim 29, wherein the composition is suitable for injection.

Claim 31 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the conjugate comprises ~~polyethylene glycol~~ a polyethylene glycol moiety.

Claim 32 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the valency platform molecule comprises ~~polyethylene glycol~~ a polyethylene glycol moiety.

Claim 33 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the conjugate comprises ~~polyethylene glycol~~ a moiety having the formula $-CH_2(CH_2OCH_2)_rCH_2-$, wherein r=0 to 300.

Claim 34 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the valency platform molecule comprises ~~polyethylene glycol~~ a moiety having the formula - $CH_2(CH_2OCH_2)_rCH_2$-, wherein r=0 to 300.

Claim 35 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the valency platform molecule comprises ~~triethylene glycol~~ a triethylene glycol moiety.

Claim 36 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 22, wherein the antibody mediated pathology is stroke.

Claim 37 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the immunogen is an external immunogen.

Claim 38 (currently amended): The ~~composition~~ conjugate of claim 37, wherein the external immunogen is a biological drug, allergen or a D immunogen associated with Rh hemolytic disease.

Claim 39 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 22, wherein the immunogen is a self-immunogen.

Claim 40 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 39, wherein the immunogen is a cardiolipin.

Claim 41 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 39, wherein the self-immunogen is that associated with thyroiditis, diabetes, stroke, male infertility, myasthenia gravis, or rheumatic fever.

Claim 42 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the immunogen and analog molecules are same chemical class.

Claim 43 (currently amended): The ~~composition~~ conjugate of claim 42, wherein the immunogen and the analog molecules are polypeptides.

Claim 44 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 22, wherein the immunogen and the analog molecules are of different chemical classes.

Claim 45 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 22, wherein the antibody-mediated pathology is an autoimmune disorder and the associated immunogen is unidentified.

Claim 46 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the analog molecules are selected from the group consisting of peptides, polypeptides, and proteins.

Claim 47 (withdrawn- currently amended): The ~~composition~~ conjugate of claim 22, wherein the analog molecules are selected from the group consisting of glycoproteins, lipoproteins, carbohydrates, lipids and lipopolysaccharides.

Claim 48 (previously presented): A method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition of claim 29.

Claim 49 (previously presented): A method of treating an individual for an antibody-mediated pathology in which undesired antibodies are produced in response to a T cell-dependent immunogen comprising administering a therapeutically effective amount of the composition of claim 29 to the individual.

Claim 50 (currently amended): A method of making the ~~composition~~ conjugate of claim 22, the method comprising forming the conjugates by covalently bonding the analog molecules to the valency platform molecule.

Claim 51 (currently amended): A method of making the composition of claim 29, the method comprising combining the ~~conjugates~~ conjugate with a pharmaceutically acceptable carrier.

Claim 52 (currently amended): The ~~composition~~ conjugate of claim 22, wherein the branching groups are derived from a functional group that is a triamine.

Claim 53 (new): The conjugate of claim 22, wherein the analog molecules are carbohydrates.

Claim 54 (new): The conjugate of claim 22, wherein the analog molecules are lipids.

Claim 55 (new): The conjugate of claim 22, wherein the analog molecules are lipopolysaccharides.

Claim 56 (new): The conjugate of claim 22, wherein the analog molecules are polypeptides.

Claim 57 (new): The conjugate of claim 22, wherein the analog molecules are peptides.

Claim 58 (new): The conjugate of claim 22, wherein the analog molecules are glycoproteins.

Claim 59 (new): The conjugate of claim 22, wherein the analog molecules are lipoproteins.

Claim 60 (new): The conjugate of claim 32, wherein the valency platform molecule comprises a polyethylene glycol moiety having a molecular weight of about 200 to about 8,000.

Claim 61 (new): The conjugate of claim 22, wherein the conjugate comprises linking groups that bind the valency platform molecule to the analog molecules.

Claim 62 (new): A method of making the conjugate of claim 61, wherein the method comprises bonding the linking groups to the valency platform molecule at the attachment sites and bonding the linker-valency platform molecule to the analog molecules to form the conjugate.

Claim 63 (new): A method of making the conjugate of claim 61, wherein the method comprises bonding the linking groups to the analog molecules and bonding the linker-analog molecules to the valency platform molecule at the attachment sites to form the conjugate.

Claim 64 (new): A method of making the conjugate of claim 61, wherein the method comprises forming the conjugates by covalently bonding the analog molecules to the chemically defined valency platform molecule via linking groups.

Claim 65 (new): A pharmaceutically acceptable composition comprising the conjugate of claim 61 and a pharmaceutically acceptable carrier.

Claim 66 (new): A pharmaceutically acceptable composition comprising the conjugate of claim 48 and a pharmaceutically acceptable carrier.

Claim 67 (new): A pharmaceutically acceptable composition comprising the conjugate of claim 49 and a pharmaceutically acceptable carrier.

Claim 68 (new): The composition of claim 22, wherein the composition comprises a valency platform molecule of the formula:




wherein n is approximately 74.

## AMENDMENTS TO THE SPECIFICATION

In the Cross Reference to Related Applications:

Please amend the paragraph on page 1 under the heading "Cross Reference to Related Applications," as shown below. A new application data sheet reflects the amendment below.

This application is a continuation of U.S. Patent Application Serial No. 08/769,041, filed December 18, 1996, which is a divisional of U.S. Patent Application Serial No. 08/453,254, filed May 30, 1995, now U.S. Patent No. 5,606,047, which is a continuation of U.S. Patent Application Serial No. 08/152,506, filed November 15, 1993, now U.S. Patent No. 5,552,391, which is a ~~continuation-in-part of U.S. Patent Application Serial No. 07/914,869 filed July 15, 1992, now U.S. Patent No. 5,276,013; and a~~ continuation-in-part of U.S. Patent Application Serial No. 08/118,055, filed September 8, 1993, U.S. Patent No. 6,060,056. The disclosures of each of these parent applications and patents are incorporated herein by reference.